BioCentury
ARTICLE | Company News

ICER panel split on value of CAR Ts

March 2, 2018 11:42 PM UTC

The Institute for Clinical and Economic Review's California Technology Assessment Forum voted that the value of Kymriah tisagenlecleucel was intermediate, while the panel was mixed on whether the value of Yescarta axicabtagene ciloleucel was intermediate or low.

Seven members voted that the value of Kymriah from Novartis AG (NYSE:NVS; SIX:NOVN) has an intermediate value compared with clofarabine, while 3 voted it had high value. The remaining vote was for low value...

BCIQ Company Profiles

Gilead Sciences Inc.

Novartis AG

BCIQ Target Profiles

CD19